Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535725 | 0.85 | IDO1 (0.46) | IDO1EP300KAT8MAPTLMNA | |
| SCHEMBL9609810 | 0.82 | CYP1A2 (0.38) | MAPTLMNAHTTCYP1A2CYP2C9 | |
| SCHEMBL9609812 | 0.82 | IDO1 (0.47) | IDO1EP300KAT8MAPTLMNA | |
| SCHEMBL28658231 | 0.81 | ESRRA (0.37) | MAPTLMNAPDGFRBPDGFRAMEN1 | |
| SCHEMBL15490440 | 0.80 | MAPT (0.37) | MAPTLMNAHTTCYP1A2CYP2C9 | |
| SCHEMBL20663706 | 0.79 | IDO1 (0.44) | IDO1EP300KAT8 | |
| SCHEMBL191864 | 0.79 | HPGD (0.46) | MAPTLMNAHTTCYP3A4GAA | |
| SCHEMBL5257415 | 0.78 | IDO1 (0.52) | IDO1EP300KAT8MAPTLMNA | |
| SCHEMBL572670 | 0.78 | GCK (0.38) | MAPTLMNAHTTCYP1A2CYP2C9 | |
| SCHEMBL15517417 | 0.77 | SRC (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717162-A | Urea derivatives as kinase inhibitors | 奥苏拉收购有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20190330155-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-10392346-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10301288-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-05-28 | — | — | US | disclosed |
| US-10144721-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2018-12-04 | — | — | US | disclosed |
| US-10125100-B2 | Kinase inhibitors | RESPIVERT LIMITED | 2018-11-13 | — | — | US | disclosed |
| US-20180319748-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010112936-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112936-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301288-B2 | Kinase inhibitors | SYK, BTK, SRC | IDO1 1262/4885EP300 1456/4885KAT8 1592/4885 |
| US-20180319748-A1 | KINASE INHIBITORS | LYN, SYK, BTK | IDO1 685/4885EP300 1819/4885KAT8 2107/4885 |
| US-10125100-B2 | Kinase inhibitors | SYK, LYN, SRC | IDO1 1609/4885EP300 1890/4885KAT8 2318/4885 |
| US-20190330155-A1 | KINASE INHIBITORS | SYK, LYN, BTK | IDO1 1330/4885EP300 1967/4885KAT8 3515/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | IDO1 1330/4885EP300 1967/4885KAT8 3515/4885 |
| US-10144721-B2 | P38 MAP kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | IDO1 2248/4885EP300 505/4885KAT8 1137/4885 |
| US-10392346-B2 | Kinase inhibitors | LYN, SYK, BTK | IDO1 685/4885EP300 1819/4885KAT8 2107/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | IDO1 1214/4885EP300 2101/4885KAT8 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.